CSTLCASTLE BIOSCIENCES INC
Services-Medical Laboratories
- Revenue
- $344M
- 3.7% YoY
- Operating margin
- -12.4%
- 576% YoY
- EBITDA
- −$2M
- 108% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$52M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired13% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $94M | $137M | $220M | $332M | $344M | 3.7% |
| Operating income | −$40M | −$73M | −$68M | $9M | −$43M | 594% |
| Net income | −$31M | −$67M | −$57M | $18M | −$24M | 232% |
| Operating cash flow | −$19M | −$42M | −$6M | $65M | $64M | 0.8% |
| Capex | $3M | $6M | $14M | $28M | $36M | 27% |
| Stock-based comp | $22M | $36M | $51M | $50M | $46M | 8.8% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 26
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $13M | 58 | 125 |
| FY2024 | $7M | $10M | 40 | 93 |
| FY2023 | $2M | $780K | 32 | 94 |
| FY2022 | $8M | $3M | 35 | 90 |
| FY2021 | $7M | $2M | 64 | 100 |